Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population.
作者信息
Li Jian-Jun
机构信息
Cardiometabolic Center, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
出版信息
JACC Asia. 2023 Jul 11;3(4):646-648. doi: 10.1016/j.jacasi.2023.06.002. eCollection 2023 Aug.
Abstract
摘要
Zotero 插件